The estimated Net Worth of Robert Alexander Ingram is at least $3.51 Milhão dollars as of 30 September 2020. Mr. Ingram owns over 5,000 units of Biocryst Pharmaceuticals stock worth over $38,650 and over the last 21 years he sold BCRX stock worth over $3,321,950. In addition, he makes $154,088 as Independent Chairman of the Board at Biocryst Pharmaceuticals.
Sign up
Mr. Ingram BCRX stock SEC Form 4 insiders trading
Robert has made over 15 trades of the Biocryst Pharmaceuticals stock since 2008, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of BCRX stock worth $152,300 on 30 September 2020.
The largest trade he's ever made was buying 50,000 units of Biocryst Pharmaceuticals stock on 22 May 2019 worth over $110,500. On average, Robert trades about 1,185 units every 26 days since 2003. As of 30 September 2020 he still owns at least 5,000 units of Biocryst Pharmaceuticals stock.
You can see the complete history of Mr. Ingram stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Ingram biography
Robert A. Ingram serves as Independent Chairman of the Board of the Company. Mr. Ingram was appointed to the Board in August 2015 and was elected Chairman of the Board in May 2017. Mr. Ingram joined Hatteras Venture Partners, a venture capital firm formed to invest primarily in early stage companies with a focus on biopharmaceuticals, medical devices, diagnostics, healthcare IT, and related opportunities in human medicine, as a General Partner in January 2007. He began his career in the pharmaceutical industry as a professional sales representative and rose through a series of roles with increasing responsibility to ultimately become CEO and Chairman of GlaxoWellcome, a pharmaceutical company. He co-led the merger and integration that formed GlaxoSmithKline (GSK) in December 2000. He subsequently served as the Chief Operating Officer and President of Pharmaceutical Operations at GSK from January 2001 to January 2003. He served as Vice Chairman Pharmaceuticals of GSK, acting as a special advisor to GSK's corporate executive team, until January 1, 2010. Mr. Ingram is Chairman of the boards of Novan, Inc., a late-stage pharmaceutical company focused on dermatology, and Viamet Pharmaceuticals Inc., a private company focused on anti-infective research. He recently retired as Chairman of the Cree Board. Mr. Ingram also serves as a member of the board of directors of HBM Healthcare Investments, Ltd., a publicly traded Swiss investment company. Mr. Ingram graduated from Eastern Illinois University with a B.S. degree in Business Administration. In addition to his professional responsibilities, Mr. Ingram formed and chaired the CEO Roundtable on Cancer at the request of former President George H. W. Bush, and he is a member of numerous other civic and professional organizations.
What is the salary of Robert Ingram?
As the Independent Chairman of the Board of Biocryst Pharmaceuticals, the total compensation of Robert Ingram at Biocryst Pharmaceuticals is $154,088. There are 9 executives at Biocryst Pharmaceuticals getting paid more, with Jon Stonehouse having the highest compensation of $2,284,300.
How old is Robert Ingram?
Robert Ingram is 77, he's been the Independent Chairman of the Board of Biocryst Pharmaceuticals since 2017. There are no older and 22 younger executives at Biocryst Pharmaceuticals.
What's Robert Ingram's mailing address?
Robert's mailing address filed with the SEC is 280 S. MANGUM STREET, SUITE 350, DURHAM, NC, 27701.
Insiders trading at Biocryst Pharmaceuticals
Over the last 24 years, insiders at Biocryst Pharmaceuticals have traded over $76,362,383 worth of Biocryst Pharmaceuticals stock and bought 4,042,003 units worth $20,848,654 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Brothers Life Sciences Capi..., eCarl L Gordon. On average, Biocryst Pharmaceuticals executives and independent directors trade stock every 31 days with the average trade being worth of $542,329. The most recent stock trade was executed by Amy E Mc Kee on 24 June 2024, trading 8,600 units of BCRX stock currently worth $54,352.
What does Biocryst Pharmaceuticals do?
biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.
What does Biocryst Pharmaceuticals's logo look like?
Complete history of Mr. Ingram stock trades at Biocryst Pharmaceuticals, Cree, Novan Inc, Regeneron Pharmaceuticals, Edwards Lifesciences Corp, Lowe`s Cos, eBlack Diamond Therapeutics Inc
Biocryst Pharmaceuticals executives and stock owners
Biocryst Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Jon Stonehouse,
President, Chief Executive Officer, Director -
Megan Sniecinski,
Senior Vice President, Chief Business Officer -
Alane Barnes,
Senior Vice President, Chief Legal Officer and Corporate Secretary -
Jon P. Stonehouse,
CEO, Pres & Exec. Director -
Yarlagadda Babu,
Senior Vice President - Drug Discovery -
William Sheridan,
Senior Vice President, Chief Medical Officer -
Dr. William P. Sheridan,
Chief Medical Officer & Sr. VP -
Dr. Yarlagadda S. Babu,
Chief Discovery Officer -
Stephen Aselage,
Independent Director -
Robert Ingram,
Independent Chairman of the Board -
Kenneth Lee,
Independent Director -
Nancy Hutson,
Independent Director -
George Abercrombie,
Independent Director -
Theresa Heggie,
Independent Director -
Helen Thackray,
Independent Director -
Dr. Helen M. Thackray FAAP, M.D.,
Chief R&D Officer -
Anthony Doyle,
Chief Financial Officer, Senior Vice President -
Alan Levin,
Independent Director -
Charles Gayer,
Senior Vice President, Chief Commercial Officer -
Allen Hodge,
Vice President and General Manager for the United States -
Michael Jones,
Executive Director - Finance, Principal Accounting Officer -
Alane P. Barnes,
Sr. VP, Chief Legal Officer & Corp. Sec. -
Michael L. Jones,
Exec. Director of Fin. & Principal Accounting Officer -
Dr. Elliott T. Berger,
Sr. VP of Regulatory Affairs -
Robert C. Stoner,
VP of HR -
John D. Bluth,
Sr. VP of Investor Relations & Corp. Communications -
Anthony Doyle,
Sr. VP & CFO -
Sanj K Patel,
Director -
Stanley C Erck,
Director -
Fred E Cohen,
Director -
Lynne Powell,
Senior VP - CCO -
Thomas R Ii Staab,
Senior Vice President and CFO -
Bros. Advisors Lp Baker Bro...,
-
John L Higgins,
Director -
Felix Baker Bros. Investmen...,
-
Zola P Horovitz,
Director -
Robert S Lowrey,
Controller, PAO -
Steven K Galson,
Director -
Steve Aselage,
Director -
Brothers Life Sciences Capi...,
-
David Mc Cullough,
VP -
Bros. Capital (Gp), Llcbake...,
-
Stephen R Biggar,
Director -
Stuart Grant,
SR VP & CFO -
Beth C Seidenberg,
Director -
William W Featheringill,
Director -
/ Tisch Capital (Gp), Llcba...,
-
Biotech Capital (Gp), Llcba...,
-
Capital (Gp), Llcbaker Juli...,
-
Mike Mills,
Principal Accounting Officer -
Partners L P/Ilbiotechnolog...,
-
Carl L Gordon,
Director -
Charles E Bugg,
CEO -
J Claude Bennett,
President -
John A Montgomery,
Director -
Jonathan M Nugent,
VP Corp Communications -
W James Alexander,
SR. VP, Chief Medical Officer -
Randall B Riggs,
VP Business Development -
Michael A Darwin,
CFO -
Randolph C Steer,
Director -
Joseph H Jr Sherrill,
Director -
William M Iii Spencer,
Director -
Charles A Sanders,
Director -
Peder Jensen,
Director -
Amy E Mc Kee,
Director -
Machelle Sanders,
Director -
Vincent Milano,
Director